DGAP-News: STRATEC extends financial guidance for 2012 to 2014
(firmenpresse) - DGAP-News: STRATEC Biomedical AG / Key word(s): Results
Forecast/Forecast
STRATEC extends financial guidance for 2012 to 2014
14.05.2012 / 20:11
---------------------------------------------------------------------
STRATEC extends financial guidance for 2012 to 2014
- Sales of between EUR 125 million and EUR 139 million expected in 2012
- Average sales growth (CAGR) of between 14% and 16% expectedover the
period 2012 to 2014 based on 2011 sales (EUR 116.6 million)
- Current production run rates and planned market launches give reasonto
expect sales to meet or potentially exceed the EUR 160 million mark in
2013
- EBIT margin of between 17% and 19% in 2012 and 2013
Birkenfeld, May 14, 2012
STRATEC Biomedical AG, Birkenfeld, Germany, (Frankfurt: SBS; Prime
Standard, TecDAX) hereby publishes its company forecast for the 2012 to
2014 financial years, taking due account of the latest developments in the
in-vitro diagnostics industry, additional customer information, and updated
internal assessments.
STRATEC expects to generate sales of between EUR 125 million and EUR 139
million in 2012. Furthermore, average sales growth (CAGR) over the period
2012 to 2014 is expected to amount to 14% to 16% based on 2011 sales (EUR
116.6 million). Based on current production run rates and planned market
launches, STRATEC still expects to achieve, and potentially exceed, the EUR
160 million sales mark originally expected for 2013. The company expects to
generate an EBIT margin of between 17% and 19% in 2012 and 2013.
The long-term planning of market launches and the minimum volume
commitments, and rolling acceptance forecasts on the part of its customers,
mean that STRATEC enjoys a high degree of transparency concerning its
performance. Medium-term forecasting is influenced by ongoing consolidation
in the diagnostics industry, planned market launches, approval dates -
which can only be anticipated to a limited extent - and analyzer system
generation changes. Due to scaling effects and given that the relative
margin contribution from the business with replacement parts is spread over
several financial years, the earnings corridor has been defined very
broadly (gross margin influenced by both growth of sales and margin
contribution of replacement parts). STRATEC is currently still increasing
its development expenditures to account for further projects, both newly
acquired or in an advanced negotiation stage.
About STRATEC
STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully
automated analyzer systems for its partners in the fields of clinical
diagnostics and biotechnology. These partners market such systems, in
general together with their own reagents, to laboratories, blood banks and
research institutes around the world. The company develops its products on
the basis of its own patented technologies.
Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard
segment of the Frankfurt Stock Exchange and are listed in the TecDAX select
index of the German Stock Exchange.
Further information can be obtained from:
STRATEC Biomedical AG
AndréLoy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
ir(at)stratec.com
www.stratec.com
End of Corporate News
---------------------------------------------------------------------
14.05.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: STRATEC Biomedical AG
Gewerbestr. 37
75217 Birkenfeld
Germany
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info(at)stratec.com
Internet: www.stratec.com
ISIN: DE0007289001
WKN: 728900
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
169839 14.05.2012
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 14.05.2012 - 20:11 Uhr
Sprache: Deutsch
News-ID 146206
Anzahl Zeichen: 5803
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 255 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: STRATEC extends financial guidance for 2012 to 2014"
steht unter der journalistisch-redaktionellen Verantwortung von
STRATEC Biomedical AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
